RS BioTherapeutics, with a valuation of $40 million, is raising funds on StartEngine. The company is bringing innovation in respiratory drug development to address inflammatory lung diseases. RS BioTherapeutics is initially focused on COPD and IPF with its innovative inhaled therapy, RSBT-001, and is opening new avenues for treatment and care. RSBT-001 is a multi-targeted immune modulator derived from cannabinoids and does not carry the side effects of using corticosteroids for targeting lung inflammation. Dean Hart founded RS BioTherapeutics in February 2021. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1.24 million. The campaign proceeds will be used for product development, safety and toxicology study design, and operations.